Literature DB >> 21322034

Identification of CCR2-binding features in Cytl1 by a CCL2-like chemokine model.

Aurelie Tomczak1, M Teresa Pisabarro.   

Abstract

Chemokines are small secreted proteins that play an important role in immune responses and have also been shown to be involved in cartilage development and contributing to pathogenesis of a variety of diseases. They present a conserved 3D structure, so-called IL8-like chemokine fold, which is supported by conserved cysteines forming intra-molecular disulfide bonds. These cysteine sequence motifs have often been used to find new chemokine family members by sequence-based database searches. However, it has been shown that different patterns can provide disulfide bonds fitting into an IL8-like architecture, which has been the key to identify new remote homologues of the IL8-like chemokine family. We report a structural-functional characterization of cytokine-like protein 1 (Cytl1) by a combination of different computational structure-based techniques. Previous studies based on sequence analysis and secondary structure predictions reported that Cytl1 might adopt a 4-helical cytokine fold. However, our detailed molecular modeling studies and structure-based functional analysis strongly suggest that Cytl1 is more likely to adopt an IL8-like chemokine fold, in particular similar to CCL2 (monocyte chemoattractant protein 1, MCP-1). Moreover, we identify in a CCL2-like 3D model of Cytl1 the necessary reported features to signal through the chemokine receptor CCR2. Those discovered structural features of Cytl1 as CCL2-like chemokine, together with the fact that both, CCL2 and Cytl1, are known to be involved in cartilage development and pathogenesis of osteoarthritis and rheumatoid arthritis, make us hypothesize that Cytl1 could be a structurally and functionally related analog of CCL2 signaling through the chemokine receptor CCR2.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21322034     DOI: 10.1002/prot.22963

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  7 in total

1.  Biochemical and biophysical characterization of cytokine-like protein 1 (CYTL1).

Authors:  Aurelie Tomczak; Kavita Singh; Apostolos G Gittis; Joohee Lee; David N Garboczi; Philip M Murphy
Journal:  Cytokine       Date:  2017-05-04       Impact factor: 3.861

2.  CYTL1 Promotes the Activation of Neutrophils in a Sepsis Model.

Authors:  Haiyan Xue; Shu Li; Xiujuan Zhao; Fuzheng Guo; Lilei Jiang; Yaxin Wang; Fengxue Zhu
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

3.  CYTL1 inhibits tumor metastasis with decreasing STAT3 phosphorylation.

Authors:  Xiaolin Wang; Ting Li; Yingying Cheng; Pingzhang Wang; Wanqiong Yuan; Qiyao Liu; Fan Yang; Qiang Liu; Dalong Ma; Shigang Ding; Jun Wang; Wenling Han
Journal:  Oncoimmunology       Date:  2019-02-18       Impact factor: 8.110

4.  CYTL1 regulates bone homeostasis in mice by modulating osteogenesis of mesenchymal stem cells and osteoclastogenesis of bone marrow-derived macrophages.

Authors:  Youngnim Shin; Yoonkyung Won; Jeong-In Yang; Jang-Soo Chun
Journal:  Cell Death Dis       Date:  2019-01-18       Impact factor: 8.469

5.  3D profile-based approach to proteome-wide discovery of novel human chemokines.

Authors:  Aurelie Tomczak; Jana Sontheimer; David Drechsel; Rainer Hausdorf; Marc Gentzel; Andrej Shevchenko; Stefanie Eichler; Karim Fahmy; Frank Buchholz; M Teresa Pisabarro
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

6.  Cytokine-Like Protein 1(Cytl1): A Potential Molecular Mediator in Embryo Implantation.

Authors:  Zhichao Ai; Wei Jing; Li Fang
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

7.  Intracellular CYTL1, a novel tumor suppressor, stabilizes NDUFV1 to inhibit metabolic reprogramming in breast cancer.

Authors:  Wenwen Xue; Xin Li; Qiang Xu; Wuhao Li; Yixuan Wang; Chengfei Jiang; Lin Zhou; Jian Gao; Ying Yu; Yan Shen
Journal:  Signal Transduct Target Ther       Date:  2022-02-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.